Pay in 4 interest-free payments of $6.02 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
Jimi E, Aoki K, Saito H, DAcquisto F, May MJ, Nakamura I, et al
Across all six studies, the safety findings were consistent: no serious adverse events, no immunogenic responses, no changes in IGF-1, no glucose or insulin disruption
If you would like to receive Claim Assistance, please contact patient services at [email protected].
A phase I/II multicenter study of single-agent foretinib as first-line therapy in patients with advanced hepatocellular carcinoma
Just remember, its super important not to take too many shots in one go
US$ 22.74
US$ 22.31
US$ 22.75
US$ 23.63
US$ 27.49
US$ 29.42
US$ 23.40
US$ 24.02
